Brukinsa marked the first cancer drug discovered in China to get an FDA green light. The approval, largely based on tumor shrinkage results from a phase 2 trial in 86 Chinese patients, “provides validation” for using primarily China data to support U.S. drug approvals, SVB Leerink analyst Andrew Berens said.
